Champions reports decrease in revenue for second one fourth of 2015 Champions Oncology.

For the three months ended October 31, 2014 and 2013, gross margins for POS were -67.9 percent and -17.5 percent, respectively. The decline in gross margin is certainly attributed to the decline in POS income and a big fixed cost element of the cost of sales. Translational Oncology Solutions : TOS revenues were $1.4 million and $1.8 million for the three months ended October 31, 2014 and 2013, respectively, a decrease of $0.4 million, or 18.8 percent.Chronix’s proprietary technology identifies disease-specific genetic fingerprints predicated on DNA fragments that are released into the bloodstream by broken and dying cells. In this new research of 575 individuals, Chronix’s assays detected and identified DNA fingerprints in the blood that indicated the presence of prostate or breast tumor with 92 percent sensitivity and 100 percent specificity, significantly outperforming the published accuracy data for current diagnostic methods. The new study outcomes will be presented within an oral program today at the 2010 ASCO Annual Meeting in Chicago.D., F.R.C.P.C., noted: These fresh data, although early, offer further evidence that Chronix’s proprietary DNA blood test may represent a fresh diagnostic and prognostic system that can identify cancer earlier and even more accurately than is currently possible.